Oct 18, 2007
Intuniv....the latest ADHD medication
In June 2007 Shire announced that it has received an approval letter from the U.S. Food and Drug Administration (FDA) for Intuniv extended release tablets. Intuniv will be used for the treatment of ADHD. It is a nonstimulant and is not a controlled substance. According to ShireNews, Matthew Emmens, CEO of Shire, said "when approved, Intuniv will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks." The medication is indicated for use in children between the ages of 6 - 17. It will be available in dosage strengths of 1 mg to 4 mg daily.